DNA promoter methylation as a diagnostic and therapeutic biomarker in gallbladder cancer.
Gallbladder cancer is an infrequent neoplasia with noticeable geographical variations in its incidence around the world. In Chile, it is the main cause of death owing to cancer in women over 40 years old, with mortality rates up to 16.5 per 100,000 cases. The prognosis is poor with few therapeutic options; in advanced cases there is only a 10% survival at 5 years.Several studies mention the possible role of DNA methylation in gallbladder carcinogenesis. This epigenetic modification affects tumor suppressor genes involved in regulation pathways, cell cycle control, cell adhesion and extracellular matrix degradation, in a sequential and cumulative way. Determining DNA methylation patterns would allow them to be used as biomarkers for the early detection, diagnosis, prognosis and/or therapeutic selection in gallbladder cancer.
Universidad de La Frontera, School of Medicine, Department of Pathology, Molecular Pathology Laboratory, BIOREN-CEGIN, Temuco, Chile. jcroa@ufro.cl.
Pablo
P
Letelier
Priscilla
P
Brebi
Oscar
O
Tapia
Juan Carlos
JC
Roa